ALTME.PA
Price:
$0.152
Market Cap:
$6.40M
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two ...[Read more]
Industry
Biotechnology
IPO Date
2016-09-30
Stock Exchange
EURONEXT
Ticker
ALTME.PA
According to TME Pharma N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 0.86. This represents a change of -2.97% compared to the average of 0.88 of the last 4 quarters.
The mean historical Current Ratio of TME Pharma N.V. over the last ten years is 1.01. The current 0.86 Current Ratio has changed 8.36% with respect to the historical average. Over the past ten years (40 quarters), ALTME.PA's Current Ratio was at its highest in in the March 2020 quarter at 4.40. The Current Ratio was at its lowest in in the March 2015 quarter at 0.
Average
1.01
Median
0.71
Minimum
0.22
Maximum
3.63
Discovering the peaks and valleys of TME Pharma N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 704.90%
Maximum Annual Current Ratio = 3.63
Minimum Annual Increase = -57.77%
Minimum Annual Current Ratio = 0.22
Year | Current Ratio | Change |
---|---|---|
2023 | 0.86 | 10.21% |
2022 | 0.78 | -57.77% |
2021 | 1.84 | -49.35% |
2020 | 3.63 | 704.90% |
2019 | 0.45 | -28.98% |
2018 | 0.64 | 185.81% |
2017 | 0.22 | -57.30% |
2016 | 0.52 | -34.14% |
2015 | 0.79 | 98.06% |
The current Current Ratio of TME Pharma N.V. (ALTME.PA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.16
5-year avg
1.51
10-year avg
1.01
TME Pharma N.V.’s Current Ratio is
Company | Current Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TME Pharma N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TME Pharma N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is TME Pharma N.V.'s Current Ratio?
How is the Current Ratio calculated for TME Pharma N.V. (ALTME.PA)?
What is the highest Current Ratio for TME Pharma N.V. (ALTME.PA)?
What is the 3-year average Current Ratio for TME Pharma N.V. (ALTME.PA)?
What is the 5-year average Current Ratio for TME Pharma N.V. (ALTME.PA)?
How does the current Current Ratio for TME Pharma N.V. (ALTME.PA) compare to its historical average?